FTC Antitrust Probe Targets Arm Holdings Over Chip Licensing Practices 
Anthropic to Brief Financial Stability Board on AI-Driven Cyber Risks 
Samsung Shares Drop as Labor Union Confirms Planned Strike 
Sonova Beats Profit Forecasts Despite Cochlear Implant Weakness 
TSMC Stake Sale Sends Vanguard Semiconductor Shares Lower 
US-China Trade Talks Sideline Chip Export Controls as Nvidia China Sales Draw Attention 
Amazon Faces Class-Action Lawsuit Over Trump Tariff Price Hikes 
Standard Chartered Targets Higher Profitability With Major Workforce Cuts 
Google, Blackstone Launch $5B AI Cloud Venture to Challenge Nvidia and CoreWeave 
Honda Shares Jump as Automaker Forecasts Profit Recovery Despite Historic Loss 
Thyssenkrupp to Shut Down Indiana Automotive Plant by March 2026 
Stellantis CEO Antonio Filosa to Reveal Turnaround Strategy Focused on U.S. Sales and China Partnerships 
Samsung Union Talks Enter Final Stage as Strike Threat Looms 
Tencent Shares Jump 4% as AI Models Move Toward Paid Commercial Services 
WILMINGTON, Del., Sept. 16, 2016 -- Rigrodsky & Long, P.A.:
- Do you, or did you, own shares of Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI)?
- Did you purchase your shares between June 24, 2015 and July 25, 2016, inclusive?
- Did you lose money in your investment?
Rigrodsky & Long, P.A. reminds shareholders of Tokai Pharmaceuticals, Inc. (“Tokai” or the “Company”) (NASDAQ:TKAI) of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. A complaint was filed in the United States District Court for the Southern District of New York on behalf of all persons or entities that purchased the common stock of Tokai between June 24, 2015 and July 25, 2016, inclusive (the “Class Period”), alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its officers (the “Complaint”).
The Complaint alleges that throughout the Class Period, defendants made materially false and misleading statements, and omitted materially adverse facts, about the Company’s business, operations and prospects. Specifically, the Complaint alleges that the defendants concealed from the investing public that: (1) there were significant structural problems with the trial design for Tokai’s pivotal Phase 3 galeterone study, ARMOR3-SV; (2) consequently, ARMOR3-SV was unlikely to succeed in meeting its primary endpoint; (3) as a result, commercialization of galeterone was less likely and/or imminent than Tokai had led investors to believe; and (4) as a result of the foregoing, the Company’s financial statements, as well as Defendants’ statements about Tokai’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis. As a result of defendants’ alleged false and misleading statements, the Company’s stock traded at artificially inflated prices during the Class Period.
If you wish to serve as lead plaintiff, you must move the Court no later than September 30, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Any member of the proposed class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.
If you purchased shares of Tokai during the Class Period, or purchased shares prior to the Class Period and still hold Tokai, and wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact Timothy J. MacFall, Esquire or Peter Allocco of Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803 at (888) 969-4242; by e-mail to [email protected]; or at: http://rigrodskylong.com/investigations/tokai-pharmaceuticals-inc-tkai.
Attorney advertising. Prior results do not guarantee a similar outcome.
CONTACT: Rigrodsky & Long, P.A. Timothy J. MacFall, Esquire Peter Allocco (888) 969-4242 (516) 683-3516 Fax: (302) 654-7530 [email protected] http://www.rigrodskylong.com
